Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments Centre

Metabolic disorders

Click on the title for more information (if available)

Lord J, Onyimadu O, Gaisford W, Rose M, Frampton G, Shepherd J.  Afamelanotide for treating erythropoietic protoporphyria: A Highly Specialised Technology, Southampton Health Technology Assessments Centre (SHTAC). 2017.

Cooper K, Harris P, Rose M, Böhler C, Chorozoglou M, Shepherd J, Frampton G. Migalastat for Fabry Disease. A Highly Specialised Technology, Southampton Health Technology Assessments Centre 2015.

Cooper K, Kalita N, Harris P, Cook A, Shepherd J, Payne L, Loveman E. Clinical-effectiveness and cost-effectiveness of elosulfase alfa for treating mucopolysaccharidosis type IVA (Morquio A syndrome) Southampton Health Technology Assessments Centre 2015

 

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×